Lubiprostone.
Sucampo Pharmaceuticals Inc and Takeda Pharmaceutical Co Ltd are developing, a ClC-2 chloride channel activator and a bicyclic member of a series of fatty acid compounds, for the potential treatment of a number of gastrointestinal conditions, including constipation, irritable bowel syndrome, postoperative bowel dysfunction and opioid bowel dysfunction.